Mr. Speaker, I have called for the clinical trials to be more transparent and open so all Canadians know the good, the bad and the ugly of clinical trials. I have also written to the Standing Committee on Health to look at potential options for improving the drug safety and transparency in the drug approval process.
I also said in February that I had asked the department to look at a variety of options for improving the drug transparency, approval process and the post-market surveillance. We are going to be producing a discussion paper on mandatory adverse reaction reporting. We are going to change the culture of drug approval in the country.